Sintilimab Plus Anlotinib as Second or Further-line Therapy for ES-SCLC Who Have Progressed After Anti-PD-1/L1 Therapy
Clinical trial NCT07022301 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07022301
- Sponsor
- First Affiliated Hospital of Wannan Medical College
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-07-01
- Primary completion
- 2027-05-01
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.